COMMUNIQUÉS West-GlobeNewswire

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
14/08/2026
BOSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, [...]
Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results
14/08/2026
– Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome – Reports Positive Clinical Update from Ongoing Pediatric Compassionate Use Program in Netherton Syndrome – [...]
Sienna Announces August Dividend
14/08/2026
MARKHAM, Ontario, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “ Common Share ”) [...]
BiomX Subsidiary Zorronet Receives Approximately $300,000 Purchase Order to Build Unified Operational Environment at Defense Technology Test and Evaluation Site
14/08/2026
Strategic project expands Zorronet’s presence in defense technology test and evaluation environments and includes site infrastructure, systems integration, a dedicated command-and-control center and coordination with [...]
Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update
14/08/2026
Exploratory analyses of patients with very severe social anxiety disorder demonstrated nominally statistically significant improvement in recently reported clinical studies FDA engagement planned during the current [...]
NOMAD POWER SOLUTIONS FILES 2026 SECOND QUARTER FORM 10-Q, PROVIDES BUSINESS UPDATE
14/08/2026
Among Recent Developments: -Corporate Name Change- -Acquisition of Leading AI Energy Infrastructure Equipment/Services Provider- -Addition to Board of Renowned Energy Sector Executive- -Key Leadership Appointments at [...]
Vivos Therapeutics Schedules Release of Second Quarter 2026 Financial Results and Conference Call
14/08/2026
Call scheduled for today, Friday, August 14, 2026, at 5:00 pm ET LITTLETON, Colo., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and [...]
Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
14/08/2026
Successfully transitioned SIL204 from regulatory preparation into an active Phase 2/3 clinical program in locally advanced pancreatic cancer, with trial initiation at Tel Aviv Sourasky Medical Center in July 2026 [...]
NurExone Reports New Preclinical Tissue-Analysis Data Supporting Potential Neuroprotective Effect of ExoPTEN in Acute Spinal Cord Injury Animal Model
14/08/2026
Tissue analysis showed significantly higher numbers of myelin-positive cells in ExoPTEN-treated animals compared with controls, providing additional preclinical biological support for previously reported functional [...]
Pfizer et Valneva annoncent l’acceptation pour revue par l’Agence européenne des médicaments (EMA) de la demande d’autorisation de mise sur le marché de leur candidat vaccin contre la maladie de Lyme
14/08/2026
Cette soumission repose sur les résultats positifs d’efficacité et de sécurité de l’étude de Phase 3 VALOR NEW YORK & LYON, France, le 14 août 2026, Pfizer Inc. (NYSE: PFE) et Valneva SE (Nasdaq: VALN; Euronext [...]
Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
14/08/2026
Submission based on favorable efficacy and safety results from Phase 3 VALOR trial NEW YORK & LYON, France, August, 14, 2026 Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced [...]
Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering
14/08/2026
SAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL) (“Zentalis” or the “Company”), a clinical oncology innovator advancing late-stage development of an investigational, [...]
Nutraville Announces MemoryFuel Launch as Interest Grows Around Creatine Monohydrate, Brain Energy, and Daily Mental Performance
14/08/2026
Tallmadge, OH, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Nutraville has announced the launch of MemoryFuel, a caffeine-free brain-health powder formulated for adults interested in supporting memory, focus support, mental [...]
More Cancer Patients Are Opting to Preserve Their Tumors
14/08/2026
New Tumor-Preservation Service Opens in Arizona, Giving Patients the Opportunity to Preserve Unadulterated Tumor Tissue for Potential Personalized Cancer Immunotherapy SCOTTSDALE, Ariz., Aug. 13, 2026 (GLOBE NEWSWIRE [...]
Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
13/08/2026
Eikon announced seven abstracts accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026 highlighting progress across Eikon’s oncology portfolio, including clinical updates for EIK1001 [...]
SRX Global Inc. Announces Fiscal Third Quarter 2026 Financial Results
13/08/2026
Net Asset Value ("NAV") of $62.9 million , or $3.22 per Common Share, Exceeding Preliminary Estimate of $3.07 per Share 1 Ended the Quarter with $36.7 million of Cash, Cash Equivalents and Restricted Cash, $65.2 million [...]
MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
13/08/2026
Reported positive results from the potentially registrational Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, supporting advancement into a Phase 3 ZEPHYR-2 trial Continued advancement of ML-007C-MA in ADP, with [...]
PetMeds® Announces First Quarter Financial Results
13/08/2026
DELRAY BEACH, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced its financial results for its first quarter ended June 30, 2026. [...]
Elutia Secures $15 Million Loan Financing from Avenue Capital Group to Fund NXT-41x Launch in $1.5 Billion Plastic and Reconstructive Surgery Market
13/08/2026
$10 million funded at closing; second $5 million tranche unlocked upon FDA 510(k) clearance of NXT-41x Preserves shareholder value by funding commercialization of Elutia's next-generation antibiotic-eluting biomatrix [...]

Pages